Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data | Future Oncology
How we treat metastatic colorectal cancer - ESMO Open
Maintenance Treatment With Capecitabine and Bevacizumab Is Effective in Metastatic Colorectal Cancer - The ASCO Post
Avastin with Xeloda as a first-line treatment for metastatic breast cancer bc_en | PDF
Avastin® (bevacizumab) Dosing | MCRC Treatment
PPT - Background PowerPoint Presentation, free download - ID:2215849
Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study - ScienceDirect
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
Colorectal Cancer – Treatments | Gastrointestinal Cancer
Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label,
Xeloda – Treatment for Metastatic Colorectal Cancer - Clinical Trials Arena
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
1175-Colorectal metastatic capecitabine and beVACizumab | eviQ
Colorectal Cancer – Treatments | Gastrointestinal Cancer
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer | British Journal of Cancer
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
Erbitux®/Avastin®/Camptosar® Appears Effective in Colorectal Cancer Patients - CancerConnect
Evidence Based Management of Newly Diagnosed Metastatic Colorectal Cancer | CME
Benefits & Risks of Treatment | Metastatic Colorectal Cancer (mCRC)| Avastin® (bevacizumab)
Xeloda – Treatment for Metastatic Colorectal Cancer - Clinical Trials Arena
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer | NEJM
Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open‐label, single‐arm, noncomparative trial - Chen - 2018 -
